Does metformin use reduce the risk of developing AMD in non-diabetic patients? Moderator Rebecca Soares, MD, and panelists Matt Starr, MD, and Nikisha Kothari, MD, review a decade-long case control-control study assessing risk of AMD in non-diabetic patients who have been taking metformin for any reason. They ask whether the study's blindspots undercut its findings, and speculate what other questions further research could answer: https://bit.ly/3OqF8Rh
Retina Today
图书期刊出版业
The latest research and clinical developments in medical retina, retinal surgery, diabetes, ocular trauma, and more.
关于我们
Retina Today delivers the latest research and developments from areas such as medical retina, retinal surgery, and more. Each issue provides insight on cutting-edge therapies and surgical techniques. A BMC Vision publication.
- 网站
-
https://retinatoday.com/
Retina Today的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 51-200 人
动态
-
Unravel complex cases through the eyes of leading specialists. https://bit.ly/48upRYN
-
-
#sponsored In this video, Dr. Jorge Calzada reviews Adaptive Fluidics on the Stellaris Elite vitrectomy platform, highlighting how this technology enables stability and efficiency during vitreoretinal procedures. Watch here: https://bit.ly/3Onub2O
-
-
Two innovative platforms, one powerhouse of education! ??? The 10th Annual Pacific Retina Club (PRC) and the International Retinal Imaging Society (IntRIS) Symposium came together to elevate retina education to new heights: https://bit.ly/4fzpPkZ
-
-
Ocugen announced encouraging preliminary results from the phase 1 portion of its phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD): https://bit.ly/3ADWirr
-
Expanding GA treatment is key, but balancing early intervention with adherence is challenging. Complement inhibitors show promise, yet need long-term commitment. Patient education & imaging can help clinicians find those who benefit most. #GeographicAtrophy https://bit.ly/4fXqhJT
-
-
Adverum Biotechnologies has released 52-week topline results from its Phase 2 LUNA trial and new 4-year follow-up data from the OPTIC Phase 1/2 study on its wet AMD gene therapy candidate Ixo-vec (AAV.7m8-aflibercept): https://bit.ly/3YVKkkJ
Adverum Announces Postive LUNA Phase 2 and OPTIC Long-Term Data on Gene Therapy for Wet AMD - Eyewire+
eyewire.news
-
Discover the Connection! This curriculum,"Connecting the Dots," dives deep into the correlation between anatomic changes and visual outcomes in retinal vascular diseases. https://bit.ly/3YPbvhf
-
Retina Today转发了
Discover this #CME curriculum, “Real-World Challenges Managing Retinal Diseases: New Solutions With Fewer Injections,” and learn from renowned experts about the latest in retinal disease management. https://bit.ly/4doehPS
-
SOCIAL: Let's check in on the pipeline from AAO '24! Dr. Durga Borkar reviews phase 2 data on ONL1204 prior to RRD surgery, and Dr. Alex Melamud summarizes phase 2/3 SAGA data on oral gildeuretinol for geographic atrophy: https://bit.ly/3AKnnsK